Aggregator
Use of Drugs With Actionable Pharmacogenetic Biomarkers and Possible Prescribing Changes Among Older People
CONCLUSIONS: CPIC Level A pharmacogenetic biomarkers are prevalent in Chinese older adults, with over 40% exposed to actionable gene-drug pairs and 36.5% requiring dose adjustments. These findings highlight the clinical imperative to integrate pharmacogenetic testing into geriatric care, prioritize CYP2C19 and SLCO1B1 testing, and develop region-specific guidelines to mitigate polypharmacy risks. Policymakers and clinicians should consider targeted implementation strategies to optimize...
The interaction between resilience framework and neuron-astrocyte-synapse dynamics in AD
The concept of resilience can be used to explain why there are differences in the degree to which the brain functions of different individuals are impaired due to aging and pathological factors associated with neurodegenerative diseases. It encompasses cognitive reserve, brain reserve, and brain maintenance. Long-term research has identified a default mode network (DMN) related to cognitive reserve. This mode can modulate the negative impact of Alzheimer's disease (AD) pathological burden on...
The impact of physical exercise on genotoxicity in older adults: a systematic review
In the context of increasing life expectancy, a higher prevalence of age-related chronic diseases is becoming more common in the health landscape, many of which are closely linked to insufficient physical exercise during lifespan. On the other hand, aging is also associated with damage to various molecules, including DNA, by reactive oxygen species. Given that both senescence and muscle mass loss are intimately linked to increased levels of DNA damage and deterioration of antioxidant defense,...
Daily briefing: Rookie researchers boost disruptive science
NIH races to spend its 2025 grant money — but fewer projects win funding
Elastin-derived extracellular matrix fragments drive aging through innate immune activation
How to find the papers you need to read — and avoid the ones you don’t
Power and profit drive what we eat: here’s why the food system needs a revolution
Want to do disruptive science? Include more rookie researchers
Public trust in science has declined since COVID — virologists need to unite around safety standards
How money, politics and technology are redefining the PhD experience in 2025
Little urchins, mischievous molluscs: my life as a sea champion
Author Correction: Selenium-alloyed tellurium oxide for amorphous p-channel transistors
Publisher Correction: Psilocybin’s lasting action requires pyramidal cell types and 5-HT2A receptors
Canada’s Supreme Court will decide fate of ostrich flock hit by bird flu
Farmers and supporters—including RFK Jr. and Dr. Oz—urge government to spare birds that survived H5N1 outbreak
Paleolithic painters had the blues
Two recent studies shine light on the earliest known artistic usages of blue pigment
Mysterious will-o’-the-wisps ignited by microlightning
Electrical discharge from microscopic bubbles offers a new explanation for fleeting flames of folklore
Worldwide Burden of Pulmonary Arterial Hypertension in Adults Aged 65 Years and Older From 1990 to 2021
CONCLUSIONS: Our findings provided a novel global perspective on the temporal trends of PAH burden in the elderly population, augmenting the existing evidence and understanding of PAH epidemiology in this demographic. Additionally, these results identify gaps in various aspects of prevention, management, and intervention strategies for PAH in the elderly.
GlyT1 inhibition promotes post-ischemic neuroprotection in the MCAO model
Glycine transporter type 1 (GlyT1) regulates extracellular glycine levels and modulates N-methyl-D-aspartate receptor (NMDAR) activity, positioning it as a promising target in excitotoxic and ischemic conditions. While previous studies have shown that GlyT1 inhibition prior to injury confers neuroprotection, its therapeutic potential in a post-ischemic context remains unclear. Here, we investigated the neuroprotective effects of NFPS, a selective GlyT1 inhibitor, administered after the induction...
Activin A protects against lipopolysaccharide/TNF-α induced damage of dopaminergic neurons both in vivo and in vitro by regulating mitochondrial fusion
There is increasing evidence that the pathogenesis of Parkinson's disease (PD) is closely related to mitochondrial dysfunction and iron deposition. Activin A (Act A) is a homodimeric cytokine from the TGF-β superfamily and has neuroprotective effects in various neurological diseases. However, the specific mechanisms by which Act A exerts a neuronal protective effect in PD remain unclear. In this study, we selected lipopolysaccharide (LPS) -induced PD model mice to investigate the mechanism of...